CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Reminder - The CTS Reentry form, CTS-00172, will be updated on Monday July 2, 2018. It's posted ...
The Q & A document from the Reentry Changes Webinar hosted on 06/06/18 has been posted in the Wh...
Honor Your StaffCelebrate Lab Week, and honor yourself and your colleagues as a vital part of the la...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...
A new Learning Center website will launch on Monday, March 30, 2020. While the link to the new Learn...
CTS will be revising some forms in use by clients on October 26, 2020. We do try to limit form chang...